BOSTON, July 11, 2025 (GLOBE NEWSWIRE) -- Cerevance, a clinical-stage biopharmaceutical company advancing multiple cell type-specific therapies for the treatment of neurodegenerative diseases and obesity, today announced upcoming presentations at the Alzheimer's Association International Conference (AAIC) 2025 being held in Toronto from July 27-31, 2025. Details of the poster presentations at AAIC 2025 are as follows: Title: CVN293, an Investigational Inhibitor of KCNK13 Targeting NLRP3-Mediated Neuroinflam ...